Dexamethasone implant in pseudophakic and nonglaucomatous subgroup of diabetic macular edema patients: A real life experience


Ozkaya A., Alagoz C., ALAGÖZ N., Gunes H., Yilmaz I., Perente I., ...Daha Fazla

European Journal of Ophthalmology, cilt.26, sa.4, ss.351-355, 2016 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 4
  • Basım Tarihi: 2016
  • Doi Numarası: 10.5301/ejo.5000725
  • Dergi Adı: European Journal of Ophthalmology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.351-355
  • Anahtar Kelimeler: Dexamethasone, Diabetic macular edema, Lens, Pseudophakia, Visual acuity
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: To evaluate the efficacy of intravitreal dexamethasone implant (IDI) for the treatment of persistent diabetic macular edema (DME) in a subgroup of pseudophakic and nonglaucomatous eyes over a 12-month follow-up period. Methods: This was a retrospective, interventional study. Patients with persistent DME who were pseudophakic and did not have a glaucoma or ocular hypertension history, or a family history of glaucoma, were included. After an initial IDI injection, reinjections were performed on an as-needed basis. Changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP), and number of injections at month 12 were evaluated. Results: The study included 50 eyes of 43 patients. Mean BCVA at baseline and at months 1, 3, 6, 9, and 12 were 0.22 ± 0.17, 0.31 ± 0.21, 0.25 ± 0.17, 0.25 ± 0.17, and 0.29 ± 0.19 Snellen equivalent, respectively (p<0.05 for all). Mean CRT at baseline and at months 1, 3, 6, 9, and 12 were 606 ± 202 µm, 330 ± 97 µm, 347 ± 104 µm, 405 ± 149 µm, 383 ± 129 µm, and 397 ± 144 µm, respectively (p<0.0001 for all). Seven of the 50 eyes (14 %) showed an increase in IOP of ≥10 mm Hg and only 2 of them (4%) needed chronic antiglaucoma medication. The mean number of injections at month 12 was 2.04 ± 0.5. Conclusions: In pseudophakic and nonglaucomatous eyes with DME, IDI was found to be beneficial in regard to visual and anatomic success and seemed safe in this selected group of patients.